Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GNRHR | P30968 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11895061 | 0.87 | KMT2A (0.50) | NPC1RAB9ANOD2TP53RXFP1 | |
| SCHEMBL17338580 | 0.86 | MAPT (0.57) | TP53MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2930311 | 0.85 | NPC1 (0.56) | NPC1RAB9ANOD2TP53RXFP1 | |
| SCHEMBL15956289 | 0.83 | LMNA (0.70) | TP53ALDH1A1LMNAP2RX3 | |
| SCHEMBL17338644 | 0.83 | LMNA (0.69) | NPC1RAB9ANOD2TP53RXFP1 | |
| SCHEMBL7056985 | 0.83 | LMNA (0.69) | NPC1RAB9AMAPTSMN1; SMN2KMT2A | |
| SCHEMBL1549166 | 0.81 | MAPT (0.76) | NPC1RAB9ANOD2TP53RXFP1 | |
| SCHEMBL17338605 | 0.81 | P2RX3 (0.57) | TP53TDP1LMNAP2RX3 | |
| SCHEMBL23914948 | 0.80 | KMT2A (0.60) | TP53KMT2ATDP1ALDH1A1CYP1A2 | |
| SCHEMBL11895496 | 0.80 | P2RX3 (0.62) | TP53LMNAP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10087144-B2 | Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 H)-quinolone | UCL BUSINESS PLC (GB) | 2018-10-02 | — | — | US | disclosed |
| EP-3145914-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL Business PLC (GB) | 2017-03-29 | — | — | EP | disclosed |
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2017-03-09 | — | — | US | disclosed |
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2017-03-09 | — | — | US | disclosed |
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2017-03-09 | — | — | US | disclosed |
| WO-2015189560-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015189560-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | CBR3, AGTR1, CBR1 | NPC1 1032/4885RAB9A 1141/4885NOD2 264/4885 |
| US-10087144-B2 | Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 H)-quinolone | AGTR1, CBR3, CBR1 | NPC1 984/4885RAB9A 1231/4885NOD2 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.